Atossa Therapeutics has secured a registered direct offering that raises $4.5 million immediately, potentially increasing to $16.5 million with warrants, aimed at advancing its oncology drug, (Z)-endoxifen. This drug, a Selective Estrogen Receptor Modulator/Degrader (SERM/D), is central to Atossa’s pipeline and is being developed for various cancers, with a pivotal trial for metastatic breast cancer underway. Despite a Q1 2026 net loss of $9.6 million and investor concerns over dilution due to share issuance, analysts remain optimistic about Atossa’s long-term growth potential, highlighting the strategic necessity of such funding maneuvers in the capital-intensive biotech sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://briefglance.com/articles/atossas-165m-gambit-fueling-cancer-trials-in-a-tough-biotech-market
